{"id":"W4324136759","doi":"10.1200/jco.2023.41.6_suppl.129","title":"Patient-reported outcomes (PROs) in KEYNOTE-921: Pembrolizumab (pembro) plus docetaxel for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Lakeridge Health","funders":"","keywords":"Docetaxel; Medicine; Placebo; Prostate cancer; Randomization; Population; Internal medicine; Urology; Gynecology; Oncology; Cancer; Clinical trial; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001888177,0.0007842096,0.001200275,0.0002753487,0.0002310667,0.000576811,0.000504688,0.0008530929,0.00507955],"category_scores_gemma":[0.001401871,0.0003342933,0.001528242,0.0003994493,0.0003813984,0.0007321872,0.0005266186,0.00222267,0.0004517398],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004948525,"about_ca_system_score_gemma":0.0005986026,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003897892,"about_ca_topic_score_gemma":0.001133419,"domain_scores_codex":[0.9991949,0.0004763715,0.00006448371,0.000103922,0.00007641682,0.00008386976],"domain_scores_gemma":[0.9989834,0.0002177652,0.0004986577,0.00004048802,0.00003996236,0.0002196612],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.913912,0.007497905,0.005474111,0.001702908,0.001938891,0.00007383007,0.00006947849,0.001072849,0.006862171,0.0001443604,0.00202859,0.05922297],"study_design_scores_gemma":[0.5830135,0.3645212,0.0419781,0.0002033097,0.003134083,0.0002963564,0.00006003499,0.001363884,0.002191921,0.0002217886,0.002976036,0.0000398215],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9864641,0.007111945,0.0004205974,0.0004742076,0.0001265761,0.001355448,0.002097796,0.00006519233,0.001884061],"genre_scores_gemma":[0.9935998,0.001822051,0.0007069883,0.0004179901,0.00009522014,0.001525483,0.001193395,0.00000605022,0.0006331349],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00507955,"threshold_uncertainty_score":0.01699275,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1430674295185643,"score_gpt":0.4883728632887113,"score_spread":0.345305433770147,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}